Skip to main content

Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

CBE ID
0066
Endorsement Status
1.1 New or Maintenance
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Fall 2024
1.3 Measure Description

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have diabetes OR a current or prior LVEF < 40% who were prescribed ACE inhibitor or ARB therapy

        • 1.14 Numerator

          Patients who were prescribed ACE inhibitor or ARB therapy

        • 1.15 Denominator

          All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have diabetes OR current or prior LVEF <40%

        • Exclusions

          Denominator Exceptions:
          Documentation of medical reason(s) for not prescribing ACE inhibitor or ARB therapy (e.g., allergy, intolerance, pregnancy, renal failure due to ACE inhibitor, diseases of the aortic or mitral valve, other medical reasons)

          Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB therapy (e.g., patient declined, other patient reasons)

          Documentation of system reason(s) for not prescribing ACE inhibitor or ARB therapy (e.g., lack of drug availability, other reasons attributable to the health care system)

        • OLD 1.12 MAT output not attached
          Attached
          1.13a Data dictionary not attached
          No
        • Most Recent Endorsement Activity
          Endorsed Cardiovascular Spring Cycle 2020
          Initial Endorsement
          Last Updated
        • Steward
          American Heart Association
          Steward Organization POC Email
          Steward Organization Copyright

          Physician performance measures and related data specifications were developed by the PCPI Foundation, the American College of Cardiology (ACC), and the American Heart Association (AHA) to facilitate quality improvement activities by physicians. These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. While copyrighted, they can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the performance measures for commercial gain, or incorporation of the performance measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and the PCPI Foundation or the ACC or the AHA. Neither the AMA, ACC, AHA, the PCPI nor its members shall be responsible for any use of these measures.

          THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.
          © 2020 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.

          Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the ACC, the AHA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications. CPT® contained in the measures specifications is copyright 2020 American Medical Association.

              • Risk adjustment approach
                Off
                Risk adjustment approach
                Off
                Conceptual model for risk adjustment
                Off
                Conceptual model for risk adjustment
                Off